Adult Diabetes Program Physicians

Arnold M Moses, MD

Arnold M Moses, MD
Appointed 08/10/53
1264 Institute For Human Performance
505 Irving Ave.
Syracuse, NY 13210

315 464-8668

Current Appointments

  • Distinguished Service Professor of Medicine

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Medicine: Endocrinology, Diabetes and Metabolism

Research Programs and Affiliations

  • Medicine


Web Resources

Education & Fellowships

  • Fellowship: SUNY Health Science Center at Syracuse, 1959
  • Fellowship: Mount Sinai Hospital and Medical Center, NYC, 1958
  • Residency: Mount Sinai Hospital and Medical Center, NYC, 1957
  • Residency: Montefiore Hospital and Medical Center, 1956
  • Residency: Montefiore Hospital and Medical Center, 1955
  • MD: SUNY Health Science Center at Syracuse, 1954

Clinical Interests

  • Metabolic bone disease; calcium disorders; diabetes insipidus

Research Interests

  • Phase III Studies of Pharmaceutical Agents in the Treatment of Postmenopausal Osteoporosis.

Specialties & Certification

  • Medicine
  • Endocrinology, Diabetes and Metabolism

Diseases & Conditions Treated

  • Diabetes Insipidus
  • Hypocalcemia/Hypercalcemia
  • Hyponatremia/Hypernatremia
  • Hypoparathyroidism/Hyperparathyroidism
  • Osteopenia
  • Osteoporosis
  • Paget's Disease of Bone
  • Pituitary Disorders
  • Pseudohypopathyroidism
  • Thyroid Disease
  • Vitamin D Related Problems


  • Adults


  • Bone Density Testing
  • Intravenous Therapy for Osteoporosis
  • Intravenous Therapy for Paget's Disease of Bone
  • Testosterone Replacement Therapy
  • Water Load Test

Current Hospital Privileges

  • Upstate University Hospital

Web Resources


Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Research Abstract

Women with postmenopausal osteoporosis, with and without fractures, are being followed in placebo controlled double blind multicenter protocols. The primary parameters of efficacy are bone density and incidence of new fractures. The agents currently being tested are the selective estrogen receptor modulator, raloxifene, and the bisphosphonate, alendronate. The current emphasis with raloxifene is to determine possible long term adverse actions. Alendronate is being administered intermittently to determine if this dosing regimen, which should be more acceptable to patients, is as effective as daily dosing in the prevention and treatment of osteoporosis.

Selected References

Moses, A.M., Thomas, D.G., Canfield, M.C., Collins, G.H.: Central diabetes insipidus due to cytomegalovirus infection of the hypothalamus in a patient with AIDS: A clinical, pathological and immunohistochemical case study.  J. Clin. Endocrinol. Metab. 88: 51-54, 2003.

Kelly, J.J., Moses, A.M: Osteoporosis in men: the role of testosterone and other sex-related factors. Curr Opin Endocrinol and Diabetes 12:452-458, 2005.

Weinstock, M.A., Moses, A.M.  Skin cancer meets vitamin D: The way forward for dermatology and public health.  J. Am. Acad. Dermatol. 61: 720-724,2009.

Clinical Profile Shortcut:
Faculty Profile Shortcut: